John Germinario, Chairman of Creative Edge Nutrition said, "I have had the pleasure of knowing David for almost fifteen years and I continue to be overly impressed with his qualifications and intellectual capacity in modern day medicine. With Bill's full support and the board's unanimous vote on Dr. Felten's appointment, it speaks volumes to the clear vision, focus, drive we uniformly have to establishing the highest industry standards in medicinal marijuana dedicated to access, accountability, quality and outcomes based medicine."
Mr. Germinario further commented, "We look forward to having David work along side our super star Sam Alawieh through his mentorship in guiding our company's continued infrastructure developments that is in line with our company vision. We are incredibly excited about the synergy in talents and believe Dr. Felten's world-class knowledge and skillset will improve our financial position and shareholder equity."
As the Chief Medical Director, Dr. David L. Felten, M.D. will join alongside our Chief Pharmacology & Acquisitions Officer, Dr. Sam Alawieh, Pharm.D. to partake in the launch of a fully operational medical board focused on good manufacturing practice, good laboratory practice, good clinical practice, compliance, vitamin, drug and naturally occurring pharmaceuticals research and development, treatment modality algorithms, and outcomes based reviews and analysis. Dr. Felten will bring scientific rigor and the highest of medical standards to the development, production, and distribution of all products from CEN Biotech.
Dr. David L. Felten was recently Vice President, Research, and Medical Director of the Research Institute at Beaumont Health System, and the founding Associate Dean for research at the Oakland University William Beaumont School of Medicine. He oversaw the Health System's research portfolio and actively participated in the development and commercialization of Beaumont's intellectual property. He established a state-of-the-art Core Molecular Laboratory and BioBank at Beaumont, strengthened the Beaumont Research Coordinating Center for oversight of multi-center clinical trials, and oversaw the conduct of all clinical translational research and basic research. Dr. Felten received a B.S. from the Massachusetts Institute of Technology in 1969, an M.D. from the University of Pennsylvania in 1973, and a Ph.D. in anatomy/neurosciences through the Institute for Neurological Sciences at the University of Pennsylvania in 1974. He has received numerous honors and awards, including the John D. and Catherine T. MacArthur Foundation Prize Fellowship, and two separate 10-year MERIT Awards from institutes (Aging, Mental Health) at the National Institutes of Health.
Previously, Dr. Felten was Dean of the School of Graduate Medical Education at Seton Hall University in South Orange, NJ, and was responsible for leadership of the residencies and fellowships in 5 large NJ hospitals, as well as graduate programs in allied health. He also served as Professor and then Chair of the Department of Neurobiology and Anatomy at the University of Rochester School of Medicine. Dr. Felten's research documented direct connections between the nervous system and the immune system, and established the foundations for the field of brain, behavior, and immunity (psychoneuroimmunology), and integrative medicine. He has published over 200 peer-reviewed publications and reviews, a majority of which focus on the links between the nervous system and the immune system, and the role these connections play in health and disease. Dr. Felten has served for many years on the National Board of Medical Examiners, helping to prepare questions for the US Medical Licensure Examinations. He also is author of the definitive neuroscience atlas, Netter's Atlas of Neuroscience, now in preparation for the third edition. He has served as the Chairman of the Scientific and Medical Advisory Board for Australian Cancer Technology (Avantogen), the Medingen Group, and The Clerisy Corporation, and is active in identification, evaluation, and commercialization of IP in medical and biological sciences, and biotechnology. He brings the same demanding scientific and medical standards to the development and understanding of products for commercialization as he does for his own research investigations.
